Oryzon Genomics SA
MAD:ORY

Watchlist Manager
Oryzon Genomics SA Logo
Oryzon Genomics SA
MAD:ORY
Watchlist
Price: 2.755 EUR -11.7%
Market Cap: 181.2m EUR

Oryzon Genomics SA
Investor Relations

Oryzon Genomics SA is a clinical stage biopharmaceutical company, which engages in the discovery, research, and development of new chemical entities, as well as conducting clinical trials. The company is headquartered in Cornella De Llobregat, Barcelona and currently employs 44 full-time employees. The company went IPO on 2015-12-10. Its compounds in clinical development include iadademstat (ORY-lOOl), an LSD1 inhibitor that is in Phase II trials for the treatment of acute myeloid leukemia and small cell lung cancer; and vafidemstat (ORY-2001), an LSD1 inhibitor optimized for the Central Nervous System (CNS), in multiple Phase II clinical trials for the treatment of CNS and psychiatric illnesses. The firm also has ORY-3001, in preclinical development for the treatment of non-oncological diseases and has additional programs to develop inhibitors against other epigenetic targets.

Show more
Loading

Earnings Calls

No Earnings Calls Available

Management

Dr. Carlos Manuel Buesa Arjol
Co-Founder, Chairman, CEO & President
No Bio Available
Mr. Enric Rello Condomines
COO & CFO
No Bio Available
Mr. Jordi Xaus Pey
Scientific Director
No Bio Available
Mr. Xavier Perpinya Ribera
Head of Internal Audit & Compliance
No Bio Available
Mr. Augusto Pinel Rubio
Secretary
No Bio Available
Mr. Emili Torrell Cortada
Director of Business Development
No Bio Available
Ms. Neus Virgili Bernado
Director of Industrial Property
No Bio Available
Dr. Michael Thomas Ropacki Ph.D.
Medical Director of SNC
No Bio Available
Ms. Sonia Paloma Gutierrez Bezon
Director of Clinical Operations
No Bio Available

Contacts

Address
BARCELONA
Cornella de Llobregat
Sant Ferran 74
Contacts
+34935151313.0
www.oryzon.com